☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Idera
Idera Stops P-II (INTRIM 1) Trial of Tilsotolimod (IMO-2125) Due to Positive Efficacy in Patients with Melanoma
May 18, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.